Affomix and City of Hope Partner on Ab Selection for Next-Gen Sequencing

City of Hope will then use Affomix's recombinant antibodies to generate proteomic profiles characteristic of a number of cancers, such as renal and prostate.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.